AVTX-803(L-Fucose) Phase III Clinical Trial Has Concluded, And Approval Is Expected in 2027.

Apr 24, 2026

Leave a message

 

一,Overview(LAD-II / SLC35C1-CDG)

 Autosomal recessive rare genetic disease caused by SLC35C1 gene mutation, leading to GDP-fucose transporter deficiency. Core manifestations: recurrent bacterial infections, severe developmental delay, Bombay phenotype; only 30-40 confirmed cases worldwide, more common in consanguineous families in the Middle East and North Africa.

二,Latest progress of AVTX-803 (the only new drug in development under LAD-II)

1. Clinical stage and data (early 2026)

 Phase III pivotal trial (NCT05462587) completed enrollment (4 global patients) with oral dose of 1400-1700mg/kg/day. sLeX expression approached normal levels, infection frequency decreased, developmental indicators improved, and Bombay phenotype relieved; 1-year data from long-term extension trial (NCT05754450) showed only mild bloating and diarrhea, no severe liver/kidney damage, and long-term safety was controllable.

2. Regulatory and Listing Outlook

 Granted FDA Orphan Drug Designation, Rare Pediatric Disease Designation, and Fast Track Designation; Phase III completed, NDA expected to be submitted in late 2026-early 2027, and approval is expected in mid-2027 (the world's first standard therapy for LAD-II).

3. Accessibility

 Only available to confirmed children in the US through clinical trials/Expanded Access; no compliant access channels in China and other regions, and AVTX-803 has not applied for clinical trials in China.

三,Other key developments

 1. Updated diagnostic criteria: Gold standard is decreased/absent sLeX (CD15s) expression on neutrophils + biallelic pathogenic mutations in SLC35C1;

 2. Gene therapy (Kresladi) has been approved for LAD-I, no gene therapy in development for LAD-II, and AVTX-803 is the only treatment hope.

 

Core Specifications and Quality Standards of AVTX-803

The core component of AVTX-803 is high-purity oral L-Fucose. The following specifications are divided into two parts: API (Active Pharmaceutical Ingredient) quality standards and key clinical research indicators, both compiled based on publicly disclosed documents from Avalo Therapeutics and clinical trial data.

Item Specification Remarks
Active Ingredient L-(-)-Fucose, CAS 2438-80-4 Molecular formula: C₆H₁₂O₅; Molecular weight: 164.16
Purity ≥99.0% (by HPLC) The clinical formulation adopts high pharmaceutical-grade purity to meet the safety requirements for long-term administration at high doses.
Appearance White crystalline powder Freely soluble in water; odorless, slightly sweet taste.
Water Content ≤0.5% (by Karl Fischer titration) To avoid stability degradation under high-humidity conditions.
Residue on Ignition ≤0.1% To control residual inorganic impurities.
Heavy Metals (as Pb) ≤10 ppm Complies with USP/EP pharmaceutical-grade standards.
Microbial Limits Total Aerobic Count ≤10³ CFU/g; Mold & Yeast ≤10² CFU/g General requirements for oral preparations.
Key Impurities No detectable exogenous sugars (glucose, galactose, etc.) or residual organic solvents To avoid interference with glycosylation processes.

 

Our high-purity L-Fucose satisfies all the aforementioned quality specifications, with endotoxin levels strictly controllable to meet pharmaceutical-grade and clinical application standards. 

 

Send Inquiry